201 related articles for article (PubMed ID: 26553671)
1. Regulatory Pathways That Facilitated Timely Registration of a New Group A Meningococcal Conjugate Vaccine for Africa's Meningitis Belt Countries.
Dellepiane N; Akanmori BD; Gairola S; Jadhav SS; Parker C; Rodriguez C; Srivastava S
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S428-33. PubMed ID: 26553671
[TBL] [Abstract][Full Text] [Related]
2. Challenges and Opportunities While Developing a Group A Meningococcal Conjugate Vaccine Within a Product Development Partnership: A Manufacturer's Perspective From the Serum Institute of India.
Kulkarni PS; Socquet M; Jadhav SS; Kapre SV; LaForce FM; Poonawalla CS
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S483-8. PubMed ID: 26553678
[TBL] [Abstract][Full Text] [Related]
3. Introduction and Rollout of a New Group A Meningococcal Conjugate Vaccine (PsA-TT) in African Meningitis Belt Countries, 2010-2014.
Djingarey MH; Diomandé FV; Barry R; Kandolo D; Shirehwa F; Lingani C; Novak RT; Tevi-Benissan C; Perea W; Preziosi MP; LaForce FM
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S434-41. PubMed ID: 26553672
[TBL] [Abstract][Full Text] [Related]
4. Technical Development of a New Meningococcal Conjugate Vaccine.
Frasch CE; Kapre SV; Lee CH; Préaud JM
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S404-9. PubMed ID: 26553667
[TBL] [Abstract][Full Text] [Related]
5. The Evolution of the Meningitis Vaccine Project.
Tiffay K; Jodar L; Kieny MP; Socquet M; LaForce FM
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S396-403. PubMed ID: 26553666
[TBL] [Abstract][Full Text] [Related]
6. From Epidemic Meningitis Vaccines for Africa to the Meningitis Vaccine Project.
Aguado MT; Jodar L; Granoff D; Rabinovich R; Ceccarini C; Perkin GW
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S391-5. PubMed ID: 26553665
[TBL] [Abstract][Full Text] [Related]
7. Communication Challenges During the Development and Introduction of a New Meningococcal Vaccine in Africa.
Berlier M; Barry R; Shadid J; Sirica C; Brunier A; Hasan H; Bouma E
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S451-8. PubMed ID: 26553674
[TBL] [Abstract][Full Text] [Related]
8. Development of a group A meningococcal conjugate vaccine, MenAfriVac(TM).
Frasch CE; Preziosi MP; LaForce FM
Hum Vaccin Immunother; 2012 Jun; 8(6):715-24. PubMed ID: 22495119
[TBL] [Abstract][Full Text] [Related]
9. Lessons from the Meningitis Vaccine Project.
LaForce FM; Djingarey M; Viviani S; Preziosi MP
Viral Immunol; 2018 Mar; 31(2):109-113. PubMed ID: 29116892
[TBL] [Abstract][Full Text] [Related]
10. Serogroup A meningococcal conjugate (PsA-TT) vaccine coverage and measles vaccine coverage in Burkina Faso--implications for introduction of PsA-TT into the Expanded Programme on Immunization.
Meyer SA; Kambou JL; Cohn A; Goodson JL; Flannery B; Medah I; Messonnier N; Novak R; Diomande F; Djingarey MH; Clark TA; Yameogo I; Fall A; Wannemuehler K
Vaccine; 2015 Mar; 33(12):1492-8. PubMed ID: 25636915
[TBL] [Abstract][Full Text] [Related]
11. Community Perspectives Associated With the African PsA-TT (MenAfriVac) Vaccine Trials.
Idoko OT; Diallo A; Sow SO; Hodgson A; Akinsola A; Diarra B; Haidara FC; Ansah PO; Kampmann B; Bouma E; Preziosi MP; Enwere GC
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S416-21. PubMed ID: 26553669
[TBL] [Abstract][Full Text] [Related]
12. Developmental strategy for a new Group A meningococcal conjugate vaccine (MenAfriVac
Kulkarni PS; Jadhav SS; LaForce FM
Hum Vaccin Immunother; 2018 May; 14(5):1103-1106. PubMed ID: 29048988
[TBL] [Abstract][Full Text] [Related]
13. Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt.
; Altmann D; Aseffa A; Bash M; Basta N; Borrow R; Broome C; Caugant D; Clark T; Collard JM; Djingarey M; Goldblatt D; Greenwood B; Griffiths U; Hajjeh R; Hassan-King M; Hugonnet S; Kimball AM; LaForce M; MacLennan C; Maiden MC; Manigart O; Mayer L; Messonnier N; Moisi J; Moore K; Moto DD; Mueller J; Nascimento M; Obaro S; Ouedraogo R; Page AL; Perea W; Pluschke G; Preziosi MP; Sow S; Stephens D; Stuart J; Thomson M; Tiendrebeogo S; Trape JF; Vernet G
Vaccine; 2013 Mar; 31(11):1453-7. PubMed ID: 23273967
[TBL] [Abstract][Full Text] [Related]
14. Risk Assessment and Meningococcal A Conjugate Vaccine Introduction in Africa: The District Prioritization Tool.
Cibrelus L; Lingani C; Fernandez K; Djingarey MH; Perea WA; Hugonnet S
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S442-50. PubMed ID: 26553673
[TBL] [Abstract][Full Text] [Related]
15. Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected].
Daugla DM; Gami JP; Gamougam K; Naibei N; Mbainadji L; Narbé M; Toralta J; Kodbesse B; Ngadoua C; Coldiron ME; Fermon F; Page AL; Djingarey MH; Hugonnet S; Harrison OB; Rebbetts LS; Tekletsion Y; Watkins ER; Hill D; Caugant DA; Chandramohan D; Hassan-King M; Manigart O; Nascimento M; Woukeu A; Trotter C; Stuart JM; Maiden M; Greenwood BM
Lancet; 2014 Jan; 383(9911):40-47. PubMed ID: 24035220
[TBL] [Abstract][Full Text] [Related]
16. Serogroup A meningococcal conjugate vaccine coverage after the first national mass immunization campaign-Burkina Faso, 2011.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2012 Dec; 61(50):1022-4. PubMed ID: 23254256
[TBL] [Abstract][Full Text] [Related]
17. Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2-29 Years.
Diallo A; Sow SO; Idoko OT; Hirve S; Findlow H; Preziosi MP; Elie C; Kulkarni PS; Parulekar V; Diarra B; Cheick Haidara F; Diallo F; Tapia M; Akinsola AK; Adegbola RA; Bavdekar A; Juvekar S; Chaumont J; Martellet L; Marchetti E; LaForce MF; Plikaytis BD; Enwere GC; Tang Y; Borrow R; Carlone G; Viviani S
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S521-30. PubMed ID: 26553684
[TBL] [Abstract][Full Text] [Related]
18. The impact of pre-existing antibody on subsequent immune responses to meningococcal A-containing vaccines.
Idoko OT; Okolo SN; Plikaytis B; Akinsola A; Viviani S; Borrow R; Carlone G; Findlow H; Elie C; Kulkarni PS; Preziosi MP; Ota M; Kampmann B
Vaccine; 2014 Jul; 32(33):4220-7. PubMed ID: 24863486
[TBL] [Abstract][Full Text] [Related]
19. Ethical Challenges and Lessons Learned During the Clinical Development of a Group A Meningococcal Conjugate Vaccine.
Martellet L; Sow SO; Diallo A; Hodgson A; Kampmann B; Hirve S; Tapia M; Haidara FC; Ndiaye A; Diarra B; Ansah PO; Akinsola A; Idoko OT; Adegbola RA; Bavdekar A; Juvekar S; Viviani S; Enwere GC; Marchetti E; Chaumont J; Makadi MF; Pallardy F; Kulkarni PS; Preziosi MP; LaForce FM
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S422-7. PubMed ID: 26553670
[TBL] [Abstract][Full Text] [Related]
20. The Meningitis Vaccine Project.
LaForce FM; Konde K; Viviani S; Préziosi MP
Vaccine; 2007 Sep; 25 Suppl 1():A97-100. PubMed ID: 17521780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
